IMUX Immunic, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IMUX matters now
Immunic, Inc. (IMUX) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.77 with -0.07% on the session and $145.8M in market capitalization; recent performance reads 1-month +22.41% and YTD +165.92%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-32.6M, and EPS of $-1.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -58.1%.
The latest indexable market news headline is "Immunic to Participate in Investor Conferences in July" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $19.00; recent insider activity includes Lundgren Erik filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.83
P/S
0.00
EV/EBITDA
0.44
DCF Value
$0.60
FCF Yield
-58.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-220.7%
ROA
-55.0%
ROIC
-72.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-32.6M | $-1.08 |
| Q4 2025 | $0.00 | $-19.3M | $-1.60 |
| FY 2025 | $0.00 | $-97.2M | $-6.24 |
| Q3 2025 | $0.00 | $-25.6M | $-1.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$14.50
Target (Median)
$19.00
Target Range
$2.50 - $22.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.39
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.